Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last $29.66 USD
Change Today +0.51 / 1.75%
Volume 3.0M
AZN On Other Exchanges
New York
As of 8:04 PM 02/12/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

2 Kingdom Street

London, W2 6BD

United Kingdom

Phone: 44 20 7604 8000

Fax: 44 20 7604 8151

heavily in clinical development and life-cycle management. Approximately 60,000 patients participate in the company’s research and development-led cardiovascular trials at approximately 5,700 sites worldwide. The company is focusing on diabetes research, which includes approximately 50 clinical studies worldwide in which approximately 40,000 patients are expected to be enrolled. The company is expanding its core capabilities and research programmes into new modalities and regenerative medicine to provide new treatment paradigms for heart failure, diabetes and chronic kidney disease. The company is developing a fixed-dose combination (FDC) of saxagliptin and dapagliflozin, which combines two complementary mechanisms designed to help more patients reach their treatment goals. Oncology Marketed Products Arimidex (anastrozole) is an aromatase inhibitor used to treat breast cancer and has been shown to be significantly superior to tamoxifen at preventing breast cancer recurrence during and beyond the five-year treatment course. Caprelsa (vandetanib) is a kinase inhibitor indicated to treat aggressive and symptomatic medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Casodex (bicalutamide) is an anti-androgen therapy used to treat prostate cancer. It is used as a 50mg tablet for advanced prostate cancer and as a 150mg tablet for locally advanced prostate cancer. Faslodex (fulvestrant) is an injectable estrogen receptor antagonist used to treat hormone receptor positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. Iressa (gefitinib) is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that acts to block signals for cancer cell growth and survival in EGFR mutation-positive (EGFR M+) advanced non-small cell lung cancer (NSCLC). Nolvadex (tamoxifen citrate) is a used breast cancer treatment outside the U.S. Lynparza (olaparib) is an oral poly adenosine diphospate-ribose polymerase inhibitor approved in the European Union (EU) for the treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer. It is approved in the U.S. for the treatment of patients with germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Zoladex (goserelin acetate implant), in one and three month subcutaneous or intra-muscular injections, is a luteinising hormone-releasing hormone agonist used to treat prostate cancer, breast cancer and certain benign gynaecological disorders. It is approved in approximately 130 countries. Respiratory, Inflammation, and Autoimmunity The company is leveraging biologics in severe asthma and chronic obstructive pulmonary disease (COPD), and developing assets in inflammatory and autoimmune disease areas. Marketed Products Accolate (zafirlukast) is an oral leukotriene receptor antagonist used for the treatment of asthma. Bricanyl Turbuhaler (terbutaline in a dry powder inhaler) is a short-acting beta2-agonist used for the acute treatment of bronchial-obstructive symptoms in asthma and COPD. Duaklir Genuair (aclidinium/formoterol) is a dual bronchodilator (long-acting muscarinic antagonist (LAMA/LABA) long-acting beta2-agonist) intended for maintenance symptom control in COPD patients and is the only LAMA/LABA with strong evidence of effect on early morning, day and nighttime symptoms. Eklira Genuair/Tudorza/Bretaris (aclidinium, a LAMA) is a 1st line treatment for symptomatic mild to moderate COPD patients in need of maintenance therapy. Oxis Turbuhaler (formoterol in a dry powder inhaler) is a fast onset, long-acting beta2-agonist used for the treatment of bronchial-obstructive symptoms in asthma and COPD. Pulmicort Turbuhaler/Pulmicort Flexhaler (budesonide in a dry powder inhaler) is an inhaled corticosteroid used for maintenance treatment of asthma. Pulmicort Respules1 (budesonide inhalation suspension) is a corticosteroid administered through a nebuliser for


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZN:US $29.66 USD +0.51

AZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $37.13 USD +0.79
AbbVie Inc $52.58 USD +0.40
Bayer AG €94.76 EUR +0.451
Celgene Corp $102.45 USD +2.86
Eli Lilly & Co $71.27 USD -0.15
View Industry Companies

Industry Analysis


Industry Average

Valuation AZN Industry Range
Price/Earnings 25.9x
Price/Sales 3.0x
Price/Book 3.9x
Price/Cash Flow 25.9x
TEV/Sales 2.9x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ASTRAZENECA PLC-SPONS ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at